Successful treatment of multiple sclerosis with refractory rheumatoid arthritis using ofatumumab: A case report
ConclusionThere is growing evidence of significant involvement of B-cells in the pathogenesis of RA and the effectiveness of B-cell depletion therapy in managing RA. Ofatumumab is an effective treatment for patients with MS and refractory RA. (Source: Clinical and Experimental Neuroimmunology)
Source: Clinical and Experimental Neuroimmunology - February 19, 2024 Category: Neurology Authors: Kenju Hara,
Masaru Togashi Tags: CASE REPORT Source Type: research
Pain in children with Bells palsy: secondary analysis of a randomised controlled trial
Conclusions
Pain in children with Bell’s palsy was infrequent and primarily occurred early in the disease course and in more severe disease. The intensity of pain, if it occurs, is very low throughout the clinical course of disease.
Trial registration number
ACTRN12615000563561. (Source: Archives of Disease in Childhood)
Source: Archives of Disease in Childhood - February 19, 2024 Category: Pediatrics Authors: Babl, F. E., Eapen, N., Herd, D., Borland, M. L., Kochar, A., Lawton, B., Hort, J., West, A., George, S., Davidson, A., Cheek, J. A., Oakley, E., Hopper, S. M., Berkowitz, R. G., Wilson, C. L., Williams, A., MacKay, M. T., Lee, K. J., Hearps, S., Dalziel, Tags: Original research Source Type: research
Outcome following acute and recurrent rheumatic fever
CONCLUSION: Clinical carditis was the most common presenting symptom in patients with ARF and RRF. The majority of patients responded positively to prednisolone. These findings highlight the predictors of valve surgery following ARF, including RRF, TR gradient ≥ 42 mmHg and LVEDD ≥ 6 cm.Abbreviations: ARF: acute rheumatic fever; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; GAS: group A beta-haemolytic Streptococcus; HF: heart failure; HR: hazard ratio; LVEDD: left ventricular end-diastolic dimension; MR: mitral regurgitation; RHD: rheumatic heart disease; RRF: recurrent rheumatic fever; TR: tricuspid r...
Source: Paediatrics and international child health - February 16, 2024 Category: Pediatrics Authors: Suchaya Silvilairat Artit Sornwai Saviga Sethasathien Kwannapas Saengsin Krit Makonkawkeyoon Rekwan Sittiwangkul Yupada Pongprot Source Type: research
Elderly woman with polyarthritis, heliotrope-like rash, lymphadenopathy and polyneuropathy
A woman in her 80s manifested polyarthritis with anti-citrullinated-protein antibody positivity in April 2021, leading to a diagnosis of rheumatoid arthritis. Although she had taken prednisolone, sulfasalazine and methotrexate, her joint inflammation persisted. In September 2021, she presented facial flushing, black pigmentation on fingers and oedematous erythema of face and eyelid like heliotrope rash (figure 1A). However, muscular weakness and tenderness were not observed, and laboratory test demonstrated no elevated levels of muscular enzymes and myositis-specific/myositis-associated autoantibodies including anti-ARS, M...
Source: Annals of the Rheumatic Diseases - February 15, 2024 Category: Rheumatology Authors: Abe, N., Bohgaki, M., Kasahara, H. Tags: ARD, Images in rheumatology Source Type: research
Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy
CONCLUSIONS: Evidence from RCTs shows that IVIg improves disability for at least two to six weeks compared with placebo, with an NNTB of 4. During this period, IVIg probably has similar efficacy to oral prednisolone and IVMP. Further placebo-controlled trials are unlikely to change these conclusions. In one large trial, the benefit of IVIg compared with placebo in terms of improved disability score persisted for 24 weeks. Further research is needed to assess the long-term benefits and harms of IVIg relative to other treatments.PMID:38353301 | DOI:10.1002/14651858.CD001797.pub4 (Source: Cochrane Database of Systematic Reviews)
Source: Cochrane Database of Systematic Reviews - February 14, 2024 Category: General Medicine Authors: Sander Rm Bus Rob J de Haan Marinus Vermeulen Ivo N van Schaik Filip Eftimov Source Type: research
The Use of Data Mining for Obtaining Deeper Insights into the Fabrication of Prednisolone-Loaded Chitosan Nanoparticles
AAPS PharmSciTech. 2024 Feb 14;25(2):38. doi: 10.1208/s12249-024-02756-3.ABSTRACTThe present work explores a data mining approach to study the fabrication of prednisolone-loaded chitosan nanoparticles and their properties. Eight PLC formulations were prepared using an automated adaptation of the antisolvent precipitation method. The PLCs were characterized using dynamic light scattering, infrared spectroscopy, and drug release studies. Results showed that that the effective diameter, loading capacity, encapsulation efficiency, zeta potential, and polydispersity of the PLCs were influenced by the concentration and molecular...
Source: AAPS PharmSciTech - February 14, 2024 Category: Drugs & Pharmacology Authors: Jehad Nasereddin Reem Al Wadi Ahlam Zaid Al-Kilani Asad Abu Khalil Mohammad Al Natour Wael Abu Dayyih Source Type: research
An open label non-inferiority randomized control trial evaluated alternate day prednisolone given daily during infections vs. levamisole in frequently relapsing nephrotic syndrome.
Initial therapies for children with frequently relapsing nephrotic syndrome include alternate-day prednisolone that is given daily during infections, or levamisole. In this open label, non-inferiority trial, 160 patients, 2 to 18-years-old with frequent relapses, were randomly assignedto receive either prednisolone (0.5-0.7 mg/kg/alternate-day, given daily during infections), orlevamisole (2-2.5 mg/kg/alternate-days) for one-year. Patients with relapses on alternate dayprednisolone at over 1 mg/kg, prior use of potent steroid-sparing therapies, eGFR under 60ml/min/1.73 m2 and significant steroid toxicity were excluded. (So...
Source: Kidney International - February 13, 2024 Category: Urology & Nephrology Authors: Aditi Sinha, Kshetrimayum Ghanapriya Devi, Suprita Kalra, Kalaivani Mani, Pankaj Hari, Arvind Bagga Tags: clinical trial Source Type: research
An open label non-inferiority randomized controlled trial evaluated alternate day prednisolone given daily during infections vs. levamisole in frequently relapsing nephrotic syndrome
Initial therapies for children with frequently relapsing nephrotic syndrome include alternate-day prednisolone that is given daily during infections, or levamisole. In this open label, non-inferiority trial, 160 patients, 2 to 18-years-old with frequent relapses, were randomly assigned to receive either prednisolone (0.5-0.7 mg/kg/alternate-day, given daily during infections), or levamisole (2-2.5 mg/kg/alternate-days) for one-year. Patients with relapses on alternate day prednisolone at over 1 mg/kg, prior use of potent steroid-sparing therapies, eGFR under 60 ml/min/1.73 m2 and significant steroid toxicity were excluded....
Source: Kidney International - February 13, 2024 Category: Urology & Nephrology Authors: Aditi Sinha, Kshetrimayum Ghanapriya Devi, Suprita Kalra, Kalaivani Mani, Pankaj Hari, Arvind Bagga Tags: clinical trial Source Type: research
